Edwards Lifesciences reports strong contributions from all product groups ??? TAVR, TTMT and surgical structural heart ??? in ...

Edwards Lifesciences Corp (EW) reports robust 9% sales growth for 2024, driven by TMTT segment and strategic acquisitions, ...

Edwards maintained its 2025 financial guidance, targeting total company sales of $5.6 billion to $6 billion, with TAVR sales of $4.1 billion to $4.4 billion, TMTT sales of $500 million to $530 million ...

Investors remain bullish on medical device makers, expecting them to benefit from still-high demand for surgical procedures, ...

Buying battle-tested dividend aristocrats can be a winning strategy for those seeking durable retirement income. Read more to ...

Reports Q4 revenue $1.39B, consensus $1.36B. Q4 TAVR sales grew 6%; constant currency sales grew 5%; Q4 TMTT sales grew 88% to $105 million ...

JAMESTOWN — Two Sanford Health Fargo cardiology providers offer outreach services at Sanford Jamestown 2nd Ave. Clinic. Outreach services are offered on the second and fourth Wednesday of every month.

Edwards Lifesciences (NYSE: EW) shares got a boost after hours today on fourth-quarter results that came in ahead of the consensus forecast.

Keeping blood pressure under control is critical. For patients who have been unable to successfully maintain that control, there is a new, cutting-edge surgical procedure available at The Heart Center ...

Edwards Lifesciences Corp (NYSE:EW) reported strong financial results for the fourth quarter of 2024, surpassing analysts' expectations with an adjusted earnings per share (EPS) of $0.59 against a ...

Edwards Lifesciences stock surged late Tuesday — and could retake its 50-day and 200-day lines — after beating fourth-quarter ...

First Horizon Corporation today announced Chief Financial Officer Hope Dmuchowski will participate in the Raymond James 46th Annual Institutional Investors Conference on March 3, 2025, at 9:15 am ...